Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Accured Expenses (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Change in Accured Expenses for 14 consecutive years, with $522000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 66.15% year-over-year to $522000.0, compared with a TTM value of -$284000.0 through Dec 2025, down 186.06%, and an annual FY2025 reading of -$284000.0, down 186.06% over the prior year.
  • Change in Accured Expenses was $522000.0 for Q4 2025 at Heron Therapeutics, down from $2.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $6.4 million in Q4 2023 and bottomed at -$8.8 million in Q2 2025.
  • Average Change in Accured Expenses over 5 years is $160400.0, with a median of $433000.0 recorded in 2023.
  • The sharpest move saw Change in Accured Expenses soared 594.04% in 2023, then plummeted 534.39% in 2024.
  • Year by year, Change in Accured Expenses stood at -$743000.0 in 2021, then tumbled by 73.89% to -$1.3 million in 2022, then skyrocketed by 594.04% to $6.4 million in 2023, then crashed by 75.84% to $1.5 million in 2024, then plummeted by 66.15% to $522000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for HRTX at $522000.0 in Q4 2025, $2.3 million in Q3 2025, and -$8.8 million in Q2 2025.